A thoughtful 30 / 60 / 90 / 180-day initial GTM plan centered around federal program funding, pharmaceutical commercial sales, and policy-driven government relations.
Valthos has three distinct buyer paths: federal program funding (DARPA, BARDA, DTRA, ARPA-H, IARPA), pharma and national labs (Amgen, Moderna, LANL, Allen Institute, Thermo Fisher), and commercial AI biosecurity (OpenAI Life Sciences alignment, reinsurance pandemic-risk feeds, DNA-synthesis screening). Each has its own sales motion, cycle length, and deal size. Perimeter (the standalone biosecurity company spun out of Ginkgo in April 2026) competes hardest on the first path. The other two are uncontested or favor Valthos's AI-native team.
In December 2025, the RAND Corporation reversed its own earlier finding that large language models could not meaningfully help with biological-weapons work. Their new paper shows three foundation models can now give accurate end-to-end instructions for recovering live poliovirus from commercially obtained synthetic DNA. Combined with the National Security Commission on Emerging Biotechnology's April 2025 final report and the ongoing H5N1 dairy spillover, the policy and budget conditions for AI biodefense are the best they have been.
Valthos's DARPA grant (an AI BTO Pitch Day catalyst award for protein-language-model work on viral variants) was originally $200K. It has been modified upward to $609K, a 204 percent increase. BTO Director Michael Koeris publicly hinted at "more incoming" in February 2026. Continuation lane, not a one-shot grant. The Office-Wide BAA has an accelerated-award path that closes contracts within 30 days of selection for proposals at or below $2M.
And here is what I would do about it →
Federal contracting cycles are 4 to 9 months from submission to award. The first 30 days are for learning the pipeline, not closing it. The 180-day plan reflects how this work actually moves.
Why this one. Direct continuation of Valthos's existing DARPA grant. The accelerated path caps proposals at $2M and delivers a contract within 30 days of selection notification. The fastest non-dilutive federal money Valthos can win. Koeris is already publicly signaling that more is incoming.
Proposal thesis. A closed-loop pipeline that integrates environmental biosurveillance signal (air, wastewater) into protein-language-model-driven countermeasure redesign. Year two scope expansion of the AI BTO catalyst work.
Non-trivial gotcha. Any subawardee (academic partner, contract research org) must also sign the Election and Attestation Form before submission. Partner alignment is a week-one Growth Ops action, not a week-twelve scramble.
Federal awards take 4 to 9 months. Pharma sales are 12 to 18 months. Reinsurance data licensing is 6 to 12 months. AI-lab safety contracts close in 3 to 6 months. The pipeline weights effort accordingly.
| Vehicle | Sponsor | Submission window | Sub → award | Size | Perimeter? |
|---|---|---|---|---|---|
| BTO Office-Wide BAA, accelerated path | DARPA BTO | Rolling through 30 Sep 2026 | 4-6 mo | ≤$2M | Likely |
| BARDA DRIVe EZ-BAA, Digital MCMs | BARDA DRIVe | Rolling | 2-3 mo | ≤$750K | No |
| ARPA-H Mission Office ISO, Health Science Futures | ARPA-H | Rolling through Mar 2029 | 4-5 mo | $5-25M | Low |
| DTRA Chem-Bio Fundamental Research BAA, topics B2 + B5 | DTRA J9 | Next topic window late 2026 | 4-6 mo | $250K-$1.5M | Likely |
| MCDC Request for Prototype Proposals (CIND, ADD) | JPEO-CBRND via ATI | RPPs released continuously | 6-9 mo | $1-50M | Yes |
| MTEC Automated Threat Detection RPP | USAMRDC + DTRA via MTEC | Award decisions Q2-Q3 2026 | 6-9 mo | $1-10M | Low |
| DIU Commercial Solutions Opening, Human Systems portfolio | DIU | Rolling areas of interest | 2-4 mo | $1-15M prototype | Yes |
| NIH SBIR Direct-to-Phase-II, NIAID antivirals | NIH NIAID DMID | Next deadline 5 Sep 2026 | 6-10 mo | ~$2M | No |
| UK Defence Innovation Biosecurity Frontiers | UKDI | Deadline 10 Jun 2026 | ~6 mo | £100-500K | No |
| Account | Why now | Sales cycle | Deal size |
|---|---|---|---|
| Moderna (biosafety + countermeasures) | OpenAI GPT-Rosalind launch partner. Co-sell through OpenAI Life Sciences team. | 9-15 mo | $500K-$2M |
| Amgen (research safety overlay) | OpenAI GPT-Rosalind launch partner. Same playbook as Moderna. | 9-15 mo | $500K-$2M |
| Thermo Fisher Scientific | OpenAI Life Sciences partner; cross-sell into Thermo's CRO and research-tools customer base. | 9-15 mo | $250K-$1M |
| Allen Institute (research safety) | OpenAI Life Sciences partner; Seattle-based. | 6-12 mo | $250K-$750K |
| Los Alamos National Laboratory | OpenAI Life Sciences research partner on AI-guided protein design. | 9-12 mo | $500K-$2M |
| Top-20 pharma DURC/PEPP compliance | Dual Use Research of Concern policy effective May 2025 requires every federally funded pharma to run institutional review. 20 named accounts. | 9-12 mo | $50K-$500K ARR each |
| Account | Why now | Sales cycle | Deal size |
|---|---|---|---|
| Munich Re Pandemic Consortium at Lloyd's | Launched February 2026. Three parametric triggers. Needs pre-WHO early-warning data feeds to price risk. | 6-12 mo | $250K-$2M ARR data feed |
| Swiss Re Life and Health pandemic peril | Public AI-cat-modeling push post-COVID. Buying scenario stress-test data. | 6-12 mo | $250K-$1M ARR |
| Microsoft Paraphrase Project consortium | Microsoft, IDT, Twist, Battelle, IBBIS, Aclid, RTX BBN, University of Birmingham. Multi-party biosafety screening initiative for synthetic biology. | 3-6 mo | Membership + research |
| OpenAI Life Sciences trusted-access program | GPT-Rosalind enterprise deployments need a biosafety overlay layer. Valthos's existing investor relationship is the warm channel. | 3-6 mo | $300K-$2M ARR |
| Biobot Analytics co-sell | Holds the September 2025 ONDCP nationwide wastewater contract. Sampling and chemistry company looking for an AI analytics partner. | 3-6 mo | Partner co-sell |
| Vehicle | Window | Why it matters |
|---|---|---|
| JE-RDAP IDIQ recompete | Current contract ends 1 Nov 2027 | $8.27B ten-year DoD chem-bio omnibus. Multi-award. Wide field of existing primes. Public RFI for the next IDIQ has not been issued. Whether Perimeter inherited the Ginkgo prime status via novation is not publicly confirmed. Being on the next bidder list reshapes Valthos's federal posture. |
| BioWatch / Securing the Cities successor under CISA | FY26 transition from DHS CWMD to CISA Infrastructure Security | Reorg is the opportunity. Any AI or data-fusion layer on top of the legacy biodetection program is greenfield. |
| IARPA biointelligence successor program | B24IC ended May 2025; successor expected | Pure AI and algorithmic work on biointelligence. Perimeter is the FELIX incumbent; Valthos competes on AI sophistication, not infrastructure. |
First federal awards land month 6 to 9. Commercial pilots can close earlier. The base case assumes disciplined pipeline reviews and reasonable conversion rates.
BTO continuation lands at month 6 or 7, plus one early commercial pilot (Munich Re data feed or OpenAI Life Sciences alignment work).
Unlocked by: BTO accelerated-path abstract submitted by month 3.
BTO plus one MCDC OTA prototype plus a DIU CSO award plus an ARPA-H Mission Office ISO plus one pharma anchor pilot.
Unlocked by: four federal abstracts in flight by month 3 plus two commercial conversations active.
Above plus BARDA full-proposal invitation converts, multi-account pharma pilots, and an insurance data-licensing tier.
Unlocked by: BARDA TechWatch meeting yields an invitation to a Stage 2 quad chart.
Perimeter (founded April 2026 as Tower Biosecurity Inc., d/b/a Perimeter Systems) is the standalone biosecurity company that spun out of Ginkgo Bioworks. $60M growth capital. Inherited Ginkgo Biosecurity's operating assets including the IARPA FELIX work (ENDAR product), traveler-based genomic surveillance at eight airports, and contracts with CDC, APHL, Defense Centers Aberdeen, and a U.S. military treatment facility. Whether the JE-RDAP prime status formally novated to Perimeter or stayed with Ginkgo Bioworks parent is not publicly confirmed. Either way, Perimeter owns physical-infrastructure detection. Valthos competes at the AI and analytics layer where its DeepMind, Arc Institute, and Broad team has the talent edge, and has two channels Perimeter does not currently fight for: pharma countermeasure adaptation and OpenAI Life Sciences alignment.
Executive Order 14292 (May 2025) restructured the federal nucleic acid synthesis screening framework. HHS wound down 22 mRNA vaccine investments at BARDA in August 2025. Federal biodefense appropriations are flat to declining in FY26. The IGSC's October 24, 2026 industry-self-binding deadline for 50-base-pair screening holds regardless of federal policy, but Valthos's policy posture needs to assume the federal framework could weaken further before the next budget cycle. Implication: do not over-index on mRNA-coded BARDA AOIs; balance federal exposure with commercial pharma and reinsurance channels.
Federal, pharma, and commercial each require different muscles. Federal demands proposal craft, government affairs, and capture management. Pharma demands biosafety domain depth and a 12-to-18-month patience. Commercial AI biosec and reinsurance demand fast, technical commercial sales. The Growth Ops role cannot move all three at speed without sequencing. My week-one ask of Rohan would be his view on which channel gets the next 30 days of disproportionate attention.
I'm Parth Doshi. Currently Financial Operations Associate at Fora Travel, running multi-currency payout operations for travel advisors. Multi-million-dollar weekly throughput, exception handling across Routable, Mercury, and advisor-credit pipelines, and the operational backbone that keeps it from breaking.
The translation to government contracting is not a leap. Same DNA: high-stakes, multi-stakeholder, deadline-driven, financially load-bearing. The difference is the vehicle.
I am making this pivot deliberately. I want to spend the next decade building the operational machine that gets serious technology into the hands of the people who need it. Valthos is exactly the right place, and the Growth Operations role reporting to Rohan is exactly the right seat to learn from.
A 20-minute call. I'll come prepared with the latest read on three of the vehicles above and a draft TechWatch quad chart for BARDA's Digital Medical Countermeasures area of interest.